Hints and tips:
...In March Pfizer swooped on Seagen, announcing a deal for a total enterprise value of $43bn, which was the largest pharmaceutical transaction announced since AbbVie agreed to buy Allergan in 2019....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The BioNTech/Pfizer jab will be dispensed in “kid-sized” doses, a third of the size of those for people aged 12 years and more....
...Pfizer last month paid $2.3bn to acquire Trillium Therapeutics, which is developing a therapy that it hopes will be transformative for treating blood cancers....
...Pfizer, AbbVie and Bristol-Myers Squibb all have blockbuster drugs due to lose exclusivity soon and have recently sealed multibillion-dollar deals....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...If you recall back in May, our colleagues dug into how the once struggling drugmaker found its footing — after fighting off a hostile takeover bid from the US rival Pfizer — to climb the ranks of the UK’...
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...“I wouldn’t read Pfizer’s actions as necessarily indicative of how we see our own programmes,” says Mr Davis....
...Job Moves Rio Tinto has appointed director Simon Thompson as its new chairman, after seriously flirting with the idea of naming Xstrata man Mick Davis to the role....
...The court’s decision today in Starr International Company, Inc. v. the United States recognizes that AIG’s shareholders are not entitled to compensation for that decision, and that the Federal Reserve’s...
...“The ideas bounced around for years but there were no believers,” recalls Tom Davis, who was director of clinical science at Medarex and is now at Celldex, another biotech company....
...bought by Pfizer....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...Endo’s Mr Davis remains untroubled....
...Simon Davis, a partner at Clifford Chance, will examine why the FCA decided to brief a solitary Telegraph journalist about a potentially market-moving review of life policies, who decided on the strategy...
...He describes turning up to the Monterey Pop Festival in 1967 wearing “a V-neck tennis sweater in the traditional white, maroon and black, over white pants”....
...This year the measure is expected to be on the ballot at 25 companies, including Pfizer, JP Morgan Chase and Verizon....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Richard Truesdell, Partner, Davis Polk & Wardwell Richard Truesdell is co-head of Davis Polk & Wardwell’s global capital markets group, and represents clients in US and international capital markets transactions...
...In the wake of the Madoff and Lehman collapses, the coming Ucits V and alternative investment fund managers directives have been framed to tighten the rules under which custodian banks operate....
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...In his famous 1911 decision in Parke-Davis & Co v HK Mulford & Co, Judge Learned Hand carved out an exception to that general rule, saying “while it is of course possible logically to call this a purification...
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
International Edition